Int J Clin Pharmacol Ther. 2024 Jul;62(7):307-310. doi: 10.5414/CP204568.
Infliximab is indicated for a wide range of diseases, and infusion reactions (IRs) have been reported after infliximab administration in 17.6% of patients in clinical practice. This study aimed to identify the risk factors for IRs before the administration of infliximab based on available patient information.
We retrospectively analyzed patients treated with infliximab. Data were compared between patients with and without IRs immediately before initiation of infliximab.
Elevated C-reactive protein (CRP) (odds ratio (OR), 2.150; 95% confidence interval (CI), 1.329 - 3.477; p = 0.002) before infliximab administration was a significant risk factor for developing an IR.
Patients with elevated CRP levels before therapy initiation may require more careful monitoring after infliximab administration.
英夫利昔单抗适用于广泛的疾病，在临床实践中，17.6%的患者在使用英夫利昔单抗后出现输注反应（IRs）。本研究旨在根据现有患者信息，确定英夫利昔单抗给药前发生 IRs 的风险因素。
我们回顾性分析了接受英夫利昔单抗治疗的患者。在开始英夫利昔单抗治疗之前，比较了有和无 IRs 的患者之间的数据。
在接受英夫利昔单抗治疗前，C 反应蛋白（CRP）升高（优势比（OR），2.150；95%置信区间（CI），1.329-3.477；p=0.002）是发生 IR 的显著危险因素。
在开始治疗前 CRP 水平升高的患者在接受英夫利昔单抗治疗后可能需要更密切的监测。
